These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35482468)

  • 21. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia.
    Patel JV; Hughes EA
    Int J Clin Pract; 2006 Aug; 60(8):914-21. PubMed ID: 16893434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease.
    Farnier M; Volpe M; Massaad R; Davies MJ; Allen C
    Int J Cardiol; 2005 Jul; 102(2):327-32. PubMed ID: 15982505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).
    Pyŏrälä K; Pedersen TR; Kjekshus J; Faergeman O; Olsson AG; Thorgeirsson G
    Diabetes Care; 1997 Apr; 20(4):614-20. PubMed ID: 9096989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of dosing time, variable compliance and circadian low-density lipoprotein production on the effect of simvastatin: simulations from a pharmacokinetic-pharmacodynamic model.
    Wright DF; Pavan Kumar VV; Al-Sallami HS; Duffull SB
    Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):494-8. PubMed ID: 21733123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study).
    Garmendia F; Brown AS; Reiber I; Adams PC
    Curr Med Res Opin; 2000; 16(3):208-19. PubMed ID: 11191012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.
    Ballantyne CM; Olsson AG; Cook TJ; Mercuri MF; Pedersen TR; Kjekshus J
    Circulation; 2001 Dec; 104(25):3046-51. PubMed ID: 11748098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT).
    Mabuchi H; Kita T; Matsuzaki M; Matsuzawa Y; Nakaya N; Oikawa S; Saito Y; Sasaki J; Shimamoto K; Itakura H;
    Circ J; 2002 Dec; 66(12):1096-100. PubMed ID: 12499612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia.
    Tuteja S; Duffy D; Dunbar RL; Movva R; Gadi R; Bloedon LT; Cuchel M
    Pharmacotherapy; 2014 Mar; 34(3):227-39. PubMed ID: 24734312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
    Collins R; Armitage J; Parish S; Sleight P; Peto R;
    Lancet; 2004 Mar; 363(9411):757-67. PubMed ID: 15016485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obesity as a risk factor for coronary events in Japanese patients with hypercholesterolemia on low-dose simvastatin therapy.
    Saito Y; Kita T; Mabuchi H; Matsuzaki M; Matsuzawa Y; Nakaya N; Oikawa S; Sasaki J; Shimamoto K; Itakura H
    J Atheroscler Thromb; 2010 Mar; 17(3):270-7. PubMed ID: 20081324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease.
    Xu Y; Wang Y; Zhi J; Qi L; Zhang T; Li X
    BMC Pharmacol Toxicol; 2017 Apr; 18(1):28. PubMed ID: 28390432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statins: new data in secondary prevention and diabetes. Pravastatin and simvastatin are the best-assessed statins.
    Prescrire Int; 2003 Aug; 12(66):143-8. PubMed ID: 12908497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The effects after withdrawal of simvastatin on brachial artery endothelial function in patient with coronary heart disease or risk factors].
    Chen H; Ren JY; Wu B; Liu X; Wang RJ; Li LJ; Luo Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Jun; 35(6):531-5. PubMed ID: 17711713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Simvastatin on the Metabolism of Fatty Acids in Combined Secondary Prevention of Coronary Heart Disease: Dosage and Gender Differences between the Effects.
    Kotlovskiy MY; Udut EV; Kairov GT; Fisenko VP; Udut VV
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(2):93-107. PubMed ID: 31916523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The MRC/BHF Heart Protection Study: preliminary results.
    Collins R; Peto R; Armitage J
    Int J Clin Pract; 2002; 56(1):53-6. PubMed ID: 11831837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of statin therapy on leptin levels in patients with coronary heart disease.
    Sun YM; Li J; Luan Y; Wang LF
    Peptides; 2010 Jun; 31(6):1205-7. PubMed ID: 20338208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.
    Olsson AG; Eriksson M; Johnson O; Kjellström T; Lanke J; Larsen ML; Pedersen T; Tikkanen MJ; Wiklund O;
    Clin Ther; 2003 Jan; 25(1):119-38. PubMed ID: 12637115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.